Farewell to 1.2 million? The country’s first universal anti-cancer magic drug was approved for clinical trials! In June 2021, a magic anti-cancer drug of 1.2 million yuan, Aquilence Injection, was approved for marketing in China, which attracted widespread attention. Within , more than 100 patients have been treated, and the revenue has reached 120 million yuan. In the face of cancer, some people are still willing to give everything in exchange for life. Can’t the price of the sky-high anti-cancer drug be reduced? Perhaps a new drug recently approved can change this situation.
First, the first in the country! The universal anti-cancer magic drug was approved for clinical trials
In the past, the anti-cancer magic drug was expensive in “private customization”. On March 17, it was independently developed by a Chinese company CTA101 UCAR-T cell injection has obtained the implied license for clinical trials from the State Food and Drug Administration. This is the first UCAR-T cell therapy product approved in my country, and it belongs to a general-purpose CAR-T therapy product.
CTA101 UCAR-T cell injection is mainly used for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia. This is the first UCAR-T cell therapy innovative drug approved in my country with China’s independent intellectual property rights, which means that my country has taken an important step in the development of universal immune cell innovative drugs, which is of milestone significance !
Before this, there are many anti-cancer drugs that have been marketed internationally. What are the specific ones? Look down together.
Second, one shot “kills” cancer cells and takes stock of the anti-cancer magic drugs that have been marketed before
CAR-T therapy is an emerging immune The full name is Chimeric Antigen Receptor T cells. It refers to the isolation of T cells in patients from blood, and the in vitro genetic manipulation of them by viral and non-viral transfection.
After the CAR-T cells are generated, they are proliferated in the laboratory to generate a large number of CAR-T cells that can be used for treatment, and then the cells are returned to the patient’s circulatory system to help identify tumors Specific antigens on cells play an anti-tumor effect. At present, a total of 7 autologous CAR-T therapies have been launched in the world. The 1.2 million yuan anti-cancer drug that has been criticized for a long time is even the cheapest one…
1. Kymriah ( $475,000/injection)
Approved for marketing on August 30, 2017, it is mainly used for the treatment of refractory B-cell acute lymphoblastic leukemia that has relapsed after at least second-line therapy.
2. Abecma ($437,900/injection)
Approved for marketing on March 26, 2021, a CAR for the treatment of multiple myeloma -T therapy treatment drug.
3. Breyanzi ($410,300/pin)
Received on February 5, 2021 Approved for marketing, CAR-T therapy for B lymphoma, follicular center lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and primary mediastinal large B-cell lymphoma drug.
4. Tecartus ($373,000/needle)
Approved for marketing on October 28, 2020, a CAR for the treatment of mantle cell lymphoma -T therapy treatment drug.
5. Yescarta ($373,000/needle)
Approved for marketing on October 18, 2017 for the treatment of at least two other treatment modalities Adult large B-cell lymphoma after failure. In March 2021, the drug was also approved for the treatment of adults with relapsed/refractory follicular lymphoma after two or multiple lines of systemic therapy.
6. Ricillance injection (1.29 million RMB/needle)
Approved for marketing on September 3, 2021 for the treatment of diffuse CAR-T therapy for large B-cell lymphoma.
7. Achilles injection (1.2 million RMB/needle)
2021 On June 22, it was approved for marketing as a CAR-T therapy drug for the treatment of adult relapsed and refractory large B-cell lymphoma.
Compared with these high-priced drugs, the new UCAR-T drugs developed in my country have great advantages, bringing new hope to countless patients. Third, the new drug is approved, one collection saves 100 people, and the price is cheaper 1. Say goodbye to private customization, and one collection saves 100 people
Autologous CAR-T therapy needs to be obtained from the patient first The extraction of T cells from the body requires 1:1 personal customization, which is not only expensive, but also requires a certain amount of time to wait.
Universal CAR-T therapy is a good solution to these dilemmas. It does not need to extract T cells from the patient’s own, and can directly use T cells from healthy people through gene editing technology. Large-scale cultivation after transformation, a healthy donor can prepare hundreds of “spots”.
2. The price is cheaper, or reduced to 1/10 of the original price Compared with autologous CAR-T therapy, the price of universal CAR-T therapy is expected to be higher To the original 1/10, allowing patients to obtain greater benefits. “Times Finance” has also interviewed professionals, predicting that the general-purpose CAR-T therapy may even be reduced to 5,000 to 30,000 yuan.
3. Immediate availability, stable curative effect, benefiting more people
Universal CAR-T therapy has the characteristics of immediate availability and can be used in the first Time to give patients medication to avoid delaying the course of the disease. And the quality of T cells provided by healthy people is relatively stable, which is undoubtedly a huge boon for some patients who cannot use autologous CAR-T cells.
Can the anti-cancer drug with such a good effect be able to treat all cancers? Can cancer be completely eliminated?
4. Can the anti-cancer drug cure all cancers?
Professor Ying Zhitao, Deputy Chief Physician of Peking University Cancer Hospital said that the therapeutic effect of CAT-T therapy on solid tumors such as digestive tract tumors and gynecological tumors is far from effective. Not as good as blood tumors. Even patients with diffuse large B-cell lymphoma who have been treated have a chance of recurrence. According to clinical statistics, about 30% to 40% of patients can survive long-term disease-free, and about 60% of patients will still relapse.
For CAR-T therapy, we must have the right attitude. Although it is effective for some special cancers, it is not without side effects. The most common side effect of CAR-T therapy is cytokine release syndrome, which can cause symptoms such as high fever, fatigue, nausea, hypotension, and cardiac insufficiency. On the way to treat cancer, many researchers are working hard to study it. I believe that more and more cancer “nemesis” will be developed in the future! Let people stop talking about discoloration about cancer.
References:
[1] “The first in China! This company’s “spot” can beat cancer”. Nanjing Jiangbei New District. 2022.3.26
[2] “What is the expensive CAR-T therapy? “. Medical Mai Tong Hematology. 2022.3.28
[3] “One shot to clear cancer cells! The 1.2 million yuan anti-cancer therapy may be reduced to 5,000 yuan in the future, and the patent for survival of the non-rich. Time Times. 2021.09.18